Co-development by Targets
Through our Next-IO™ programs, we are proposing hope for patients in need.
Looking for partners to facilitate your research in therapy discovery? At Creative Biolabs, our scientists are dedicated to building Next-IO™ programs and boosting the development of monoclonal antibody drugs or other combination therapies for cancer treatment. From our standpoint, there is nothing more important than helping patients who are suffering. We are optimal cooperators with shared goals to move forward in oncotherapy.
Focus on Tumor Microenvironment (TME)
Cancers are not just a bunch of invasive and malignant cells, but also complex “organs” consisting of many other recruited cells.
The tumor microenvironment (TME) is constructed by the interaction between malignant cells and non-transformed cells. Our Next-IO™ programs focus on the targets in tumor microenvironment that are related to immune cells. Cells in TME contain T lymphocytes, B lymphocytes, natural killer (NK) and natural killer T (NKT) cells, tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), dendritic cells (DCs), tumor-associated neutrophils (TANs), cancer-associated fibroblasts, adipocytes, vascular endothelial cells, pericytes, and lymphatic endothelial cells, etc. There are a wide range of pre-clinical and clinical approaches targeting tumor microenvironment. It is believed that TME is important in designing novel cancer therapies. Please visit some sample programs as follows to learn more.
Next-IO™ T Cell-related Therapeutics
Next-IO™ APC-related Therapeutics
Next-IO™ NK Cell-related Therapeutics
Next-IO™ Tumor-Associated Antigens
Next-IO™ Macrophages-Related Therapeutics
Next-IO™ B Cell related Therapeutics
Next-IO™ Chemokines & Chemokine Receptors-Related Therapeutics
COVID-19 Recovered Patient-Derived Anti-SARS-CoV-2 Therapeutic Antibody Development
Next-IO™ Alzheimer's Disease Therapeutics
Next-IO™ Immunometabolism Therapeutics
Next-IO™ Tumor Microenvironment Therapeutics
Next-IO™ Tumor-Intrinsic Resistance Therapeutics
Timeline of Next-IO™ Programs
With extensive expertise in comprehensive program development and problem-solving, we ensure regular progress updates for our partners and aim to deliver the final program within approximately 1.5 years. The specific timeline will vary based on individual cases. Below is a simplified draft schedule for quick reference.
Fig.1 The Projected Timeline of Next-IO™ Programs.
Ready to Get an Instant Quote?
Trust Creative Biolabs to deliver tailored solutions, offering precise and actionable insights to support every step of your immuno-oncology research journey.
Creative Biolabs provided excellent support for our monoclonal antibody project under the Next-IO™ program. The detailed profiling of immune cells in the tumor microenvironment allowed us to develop more precise therapeutic approaches. Their professionalism and timely delivery exceeded our expectations.
—Emma W., Senior Scientist
Working with Creative Biolabs on COVID-19-related therapeutic antibodies was highly productive. Their advanced Next-IO™ platforms helped us isolate potent candidates efficiently. The team's deep knowledge of immuno-oncology and smooth collaboration enabled rapid project progression.
—James R., Biotechnology Director
Creative Biolabs provided unparalleled support in developing Alzheimer’s disease therapeutics. Their Next-IO™ program not only offered technical expertise but also ensured comprehensive monitoring and swift project advancement, making them a trusted partner in our research.
—Emily C., Neuroscience Researcher